Further supporting a potential role for the NF‐κB2 pathway in melanoma resistance to targeted therapy is the observation that the drug‐resistant undifferentiated and neural crest‐like subpopulations display a strong enrichment for the NIK/NF‐κB signaling pathway (Tsoi et al, 2018). The gene discussed is NFKB2; the disease is melanoma.